NYSE:BMY - Bristol-Myers Squibb Stock Price, Forecast & News

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 5th. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share on Monday, February 3rd. This represents a $1.80 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.41. View Bristol-Myers Squibb's Dividend History.

Bristol-Myers Squibb Co (NYSE:BMY) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $1.06 by $0.11. The biopharmaceutical company had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The firm's revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 EPS. View Bristol-Myers Squibb's Earnings History.

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Bristol-Myers Squibb.

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Bristol-Myers Squibb issued an update on its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $4.25-4.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.29.

15 equities research analysts have issued 12-month price targets for Bristol-Myers Squibb's shares. Their forecasts range from $53.00 to $80.00. On average, they expect Bristol-Myers Squibb's share price to reach $62.33 in the next year. This suggests that the stock has a possible downside of 6.6%. View Analyst Price Targets for Bristol-Myers Squibb.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.

News articles about BMY stock have been trending positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Bristol-Myers Squibb.

Bristol-Myers Squibb saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 74,320,000 shares, a decline of 23.6% from the November 28th total of 97,220,000 shares. Based on an average daily volume of 17,560,000 shares, the days-to-cover ratio is presently 4.2 days. Currently, 4.6% of the company's shares are short sold. View Bristol-Myers Squibb's Current Options Chain.

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Chicago Bridge & Iron (CBI), Diebold Nixdorf (DBD), Bank of America (BAC), Pfizer (PFE), Verizon Communications (VZ), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Bristol-Myers Squibb's stock is owned by many different of retail and institutional investors. Top institutional investors include PGGM Investments (0.12%), DNB Asset Management AS (0.09%), Artemis Investment Management LLP (0.07%), Hexavest Inc. (0.06%), Gateway Investment Advisers LLC (0.06%) and Nisa Investment Advisors LLC (0.06%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb.

BMY stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Rhenman & Partners Asset Management AB, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Measured Wealth Private Client Group LLC, Boltwood Capital Management, OmniStar Financial Group Inc., Stewart & Patten Co. LLC and Baxter Bros Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago and Louis S Schmukler. View Insider Buying and Selling for Bristol-Myers Squibb.

BMY stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Hexavest Inc., Artemis Investment Management LLP, Dudley & Shanley Inc., Nisa Investment Advisors LLC, Gateway Investment Advisers LLC, Penn Davis Mcfarland Inc. and TIAA FSB. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BMY stock can currently be purchased for approximately $66.72.

Bristol-Myers Squibb has a market capitalization of $108.71 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.View Additional Information About Bristol-Myers Squibb.

The official website for Bristol-Myers Squibb is http://www.bms.com/.

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]